Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Thrombocytopenia 1Lymphoma 1Intraocular Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1

Interventions

eltrombopag 14romiplostim 7avatrombopag 7Platelet Transfusion 6Cytarabine 6Radiotherapy 4Filgrastim 4Etoposide 4Carboplatin 4oprelvekin 3Tranexamic Acid 3Peripheral Blood Stem Cell Transplantation 3Daunorubicin 3Cyclophosphamide 3Busulfan 3hetrombopag 2fludarabine phosphate 2Tretinoin 2Thrombopoietin 2Lenalidomide 2Interleukin-11 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyclosporine 2Amplified Fragment Length Polymorphism Analysis 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2sodium thiosulfate 1siltuximab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocytopenia × sodium thiosulfate × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡